Vitrase

Treatment for Hypodermoclysis, Subcutaneous Urography

Review of ISTA Pharmaceuticals' New Drug Application for Vitrase for Use as a Spreading Agent Extended 90 Days by FDA


Agency to Complete Review by May 5, 2004

IRVINE, Calif., February 6, 2004 -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) today announced that the U.S. Food & Drug Administration (FDA) plans to complete review of ISTA's Vitrase for Use as a Spreading Agent New Drug Application (NDA) by May 5, 2004, a 90-day extension of the original action date. According to the FDA's written notification to ISTA, the extension will allow "full review of the submission," including the Company's amendment to the NDA submitted late last year. Under the Prescription Drug User Fee Act (PDUFA), the FDA can reset the action date to review additional data submitted within three months of the original PDUFA action date.

"We have maintained close contact with the agency throughout the process of filing the NDA and believe that any remaining issues can be resolved within the extension period," stated Vicente Anido, Jr., Ph.D., ISTA's Chief Executive Officer. "We very much look forward to working closely with the FDA to complete their review within the extended period."

Source: ISTA Pharmaceuticals, Inc. www.istavision.com

Posted: February 2004

Related Articles

Vitrase (hyaluronidase) FDA Approval History

View comments

Hide
(web1)